



Viread[®] (tenofovir disoproxil fumarate) – First-time generic

- On December 15, 2017, [Teva Pharmaceuticals launched](#) an [AB-rated](#) generic version of Gilead's [Viread \(tenofovir disoproxil fumarate\)](#) 300 mg tablets.
 - Teva will have 42 days of exclusivity with additional manufacturers able to launch generics if they receive FDA approval on January 26, 2018.
- Viread is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 2 years of age and older, and for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
- Viread is also available as tablets in 150 mg, 200 mg and 250 mg strengths and an oral powder containing 40 mg per level scoop.
- Viread carries a boxed warning for posttreatment exacerbation of hepatitis.
- Viread had annual U.S. sales of \$762 million as of October 2017 per IMS data.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.